SecBot SecBot
SECBOTREPLAY Home › Report › PYXS

PYXS · Pyxis Oncology entered into a securities purchase agreement for a $50…

Pyxis Oncology, Inc. · 8-K filed Jul 2, 2026 at 16:20 ET

At the news

MIXEDIMPACT 6/10

8-K filed Jul 2, 2026 at 16:20 ET

Pyxis Oncology entered into a securities purchase agreement for a $50 million private placement (plus up to $64 million from warrants) led by BVF Partners, issuing 19.6 million shares at $2.551/share and warrants exercisable at $3.289. Proceeds extend cash runway into Q2 2027 and fund MICVO clinical milestones. The financing is dilutive (~28% of current float) but provides critical capital for a pre-revenue biotech.

  • $50M upfront gross proceeds from sale of 19,600,153 shares at $2.551/share
  • Warrants to purchase up to 19,600,153 shares at $3.289/share, exercisable after MICVO data disclosure or Oct 1, 2026, expiring July 2, 2029
  • Potential total gross proceeds of ~$114M if warrants fully exercised for cash
  • Cash runway extended into Q2 2027

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access